Innovent Biopharmaceutical Transformation
Building Leading Commercial Franchise with Expanding
Approved and Late-stage Portfolio in Near Term
Robust Late Stage Assets for Growth
Oncology/Non-Oncology
TA
Target/Asset
PD-1 (sintilimab)
Product
CD20 (rituximab)
TYVYTⓇ
HALPRYZAⓇ
Status
Launched
Indication
CHL
Launched
NHL
TYVYT
Broad Patients
and Big Market
TYVYTⓇ
CYRAMZAⓇ
IBI-362
PCSK9
达攸同®
W
BYVASDAⓇ
VEGF/C
CTLA-4
Sintilimab injection
Hematology
BCR/ABL (olverembatinib)
NAILIKE
Launched
CML
BCMA CART
(Equecabtagene Autoleuce)
IBI-326
NDA in 1H2022
MM
PI3K (parsaclisib)
IBI-376
49
PD-1 (sintilimab)
TYVYTⓇ
CYRAMZA™
PD-1 (sintilimab)
TYVYTⓇ
ramucirumab injection
10 mg/ml solution
Lung Cancer
RET (selpercatinib)
ROS1 (taletrectinib)
RETSEVMO®
IBI-344
Pivotal Ph2
Launched
Launch in 2022
Launch in 2022
FL
1L sqNSCLC; 1L nsq NSCLC
Pivotal Ph2
HALPRYZAⓇ
SULINNOⓇ
PemazyreⓇ
IL-23
Clear Unmet
Olverembatinib
PDE4
Need and Good
RETESVMO®
Opportunity
达伯华
達伯坦>
BCMA CAR-T
Pemazyre (tablets)
ROS1/NTRK
苏立信
PI3K8*
奧爾巴尼 pivorembatinib
#
KRAS G12C
PD-1 (sintilimab)
IBI-351
Ph1
TYVYTⓇ
Launched
EGFR+ NSCLC
RET+ NSCLC
ROS1+ NSCLC
KRAS+ NSCLC
1L HCC
VEGF-A (bevacizumab)
BYVASDAⓇ
Launched
1L HCC
Retevmo™
Liver Cancer
VEGFR2 (ramucirumab)
CTLA-4 (ipilimumab)
FGFR1/2/3 (pemigatinib)
CYRAMZAⓇ
Launched
2L GC
IBI-310
PEMAZYRE®
Ph3
Launched
1L HCC
PD-1 (sintilimab)
PD-1 (sintilimab)
耐立克
Gastrointestinal
VEGFR2 (ramucirumab)
KRAS G12C
CLDN18.2
TYVYTⓇ
TYVYTⓇ
CYRAMZAⓇ
IBI-351
IBI-360;IBI-345;IBI-389
Launch in 2022
Launch in 2022
CCA
1L GC
1L ESCC
Launched
Ph1
Ph1
Franchise and Synergy in TAs
Gynecological
Metabolic
PD-1 (sintilimab)
CTLA-4 (ipilimumab)
VEGF-A (bevacizumab)
PCSK-9 (tafolecimab)
GLP1/GCGR
TYVYTⓇ
IBI-310
BYVASDAⓇ
TNFα (adalimumab)
IBI-306
IBI-362
SULINNOⓇ
Autoimmune
IL-23
IBI-112
PDE4 (orismilast)
IBI-353
Ph3 in 2023
Oncology | Metabolic | Autoimmune | Ophthalmology
Ophthalmology VEGF/C (efdamrofusp alfa)
IBI-302
Ph2
Innovent
Confidential
Copyright©2022 Innovent
Pivotal Ph2
Pivotal Ph2
Launched
NDA in 1H2022
Ph3 in 2022
Launched
Ph3 in 2022
2L GC
CRC, PC, etc.
GC, PC, etc.
2L CC
2L CC
OC, CC
nFH, HeFH
Diabetics, Obesity
RA, AS, Psoriasis, PJIA, Uveitis
Psoriasis; Ulcerative colitis
Psoriasis; Atopic Dermatitis
nAMD
17View entire presentation